Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Blood (2024) 144 (Supplement 1): 1332.

https://doi.org/10.1182/blood-2024-194024

Published: 2024

Journal Articles

Patient-Derived Models of Clonal Hematopoiesis Point to Cell-Intrinsic and -Extrinsic Contributions to Clonal Dominance and Lineage Imbalances

Mareike Peters, Jiajun Xie, Sergiu Pasca, Hamzah Kharabsheh, Anna S Nam, Lukasz P. Gondek, Gabriel Ghiaur

Blood (2024) 144 (Supplement 1): 1294.

https://doi.org/10.1182/blood-2024-208399

Published: 2024

Journal Articles

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Simona Pagliuca, Carmelo Gurnari, Arda Durmaz, Ashwin Kishtagari, Zain Virk, Lukasz P. Gondek, Matthew Guo, Maria Bettinotti, Mark B Juckett, Qing Cao, Suresh Kumar Balasubramanian, Vikram Dhillon, Ben K. Tomlinson, Koen van Besien, Alice Aarnink, Marie Thérèse Rubio, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 927.

https://doi.org/10.1182/blood-2024-210565

Published: 2024

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Mitochondrial Heteroplasmy Is a Novel Predictor of Chronic Lymphocytic Leukemia Risk

Sergiu Pasca, Yun Soo Hong, Wen Shi, Daniela Puiu, Nicole J Lake, Monkol Lek, Eliseo Guallar, Dan E Arking, Lukasz P. Gondek

Blood (2024) 144 (Supplement 1): 4054.

https://doi.org/10.1182/blood-2024-210250

Published: 2024

Journal Articles

CYP26 Activity Maintains the Bone Marrow Niche and Stem Cell Homeostasis

Teodora Diana Supeanu, Cristian Moldovan, Laura Palau, Sergiu Pasca, Patric Teodorescu, Lukasz P. Gondek, Gabriel Ghiaur

Blood (2023) 142 (Supplement 1): 2702.

https://doi.org/10.1182/blood-2023-189136

Published: 2023

Journal Articles

Outcome Prediction in DDX41 -Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Carmelo Gurnari, Hideki Makishima, Arda Durmaz, Ryunosuke Saiki, Guilherme Mendes Sapinho, Alex Bataller, Lukasz P. Gondek, Yasuhito Nannya, Steve Best, Pramila Krishnamurthy, Hussein Awada, Enrico Attardi, Valeria Visconte, Maria Teresa Voso, Amy E. DeZern, Guillermo Garcia-Manero, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 142 (Supplement 1): 316.

https://doi.org/10.1182/blood-2023-178116

Published: 2023

Journal Articles

Refining CHIP in population data sets

Lukasz P. Gondek

Blood (2023) 141 (18): 2163–2164.

https://doi.org/10.1182/blood.2023019801

Published: 2023

Journal Articles

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Sergiu Pasca, Saurav D. Haldar, Alexander J. Ambinder, Jonathan Webster, Tania Jain, William Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 10629–10631.

https://doi.org/10.1182/blood-2022-169148

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status

Michael J. Hochman, Alexander J. Ambinder, Lukasz P. Gondek, Amy E. DeZern

Blood (2022) 140 (Supplement 1): 3387–3388.

https://doi.org/10.1182/blood-2022-164757

Published: 2022

Journal Articles

Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Sergiu Pasca, Matthew Guo, Shiyu Wang, Kristin Stokvis, Audra Shedeck, Aparna Pallavajjala, Lisa Haley, Cynthia Shams, Roshni Pallavajjala, Christopher D. Gocke, Amy E. DeZern, Ravi Varadhan, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 3429–3430.

https://doi.org/10.1182/blood-2022-169413

Published: 2022

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Matthew Scarlotta, Jonathan Webster, Matthew Newman, Cory Schulz, Kristin Stokvis, Alexander J. Ambinder, Tania Jain, William Brian Dalton, Lukasz P. Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Christopher S. Hourigan, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Mark J. Levis

Blood (2022) 140 (Supplement 1): 11747–11748.

https://doi.org/10.1182/blood-2022-160300

Published: 2022

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease

Sergiu Pasca, Shiyu Wang, Susan Langan, Aparna Pallavajjala, Lisa Haley, Christopher D Gocke, Wendy S Post, Matthew Budoff, Sabina Haberlen, Todd Brown, Joseph Margolick, Richard F. Ambinder, Lukasz P. Gondek

Blood (2021) 138 (Supplement 1): 4298.

https://doi.org/10.1182/blood-2021-152860

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Whole Genome Sequencing Uncovers a Rare Germline Variant in ATM Associated with Familial Myeloproliferative Neoplasms

Shiyu Wang, Hang Chen, Eddie Imada, Jack Ghannam, Clifton L. Dalgard, Camille Alba, Christopher S. Hourigan, Luigi Marchionni, Alison R. Moliterno, Lukasz P. Gondek, Evan M. Braunstein

Blood (2021) 138 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2021-153317

Published: 2021

NARROW

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Patient-Derived Models of Clonal Hematopoiesis Point to Cell-Intrinsic and -Extrinsic Contributions to Clonal Dominance and Lineage Imbalances

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Mitochondrial Heteroplasmy Is a Novel Predictor of Chronic Lymphocytic Leukemia Risk

CYP26 Activity Maintains the Bone Marrow Niche and Stem Cell Homeostasis

Outcome Prediction in DDX41 -Mutant Myelodysplastic Syndromes Is Not Possible with General Disease Schemes and Requires a Dedicated Risk Scoring System

Refining CHIP in population data sets

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status

Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Whole Genome Sequencing Uncovers a Rare Germline Variant in ATM Associated with Familial Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only